

## 1ST ANNUAL MEETING 16-18 AUGUST 2019 GRAND HYATT, KOCHI

## SCIENTIFIC PROGRAM **16TH AUGUST 2019** DAY 1 TIME **TOPIC** SPEAKER (S) CHAIR (S) Abstract presentation (7 selected oral from the Dr. Sadashivudu Gundeti 05:00 - 06:10 PM EHA/ASH/ASCO) Dr. Mathew Thomas **TITLE PRESENTER** 1.E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma 2. Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1);: results of the AML study group 3. The first-in-class anti-cd47 antibody Hu5F9-G4 is active and well tolerated alone or in combination with 1.Dr Ranjit Sahoo azacitidine in AML and MDS patients: initial phase 1b 2.Dr Gaurav Prakash results 3.Dr Lingaraj Nayak 4. Combination therapy using Asciminib plus Imatinib in 4.Dr Chandran Nair 5.Dr Smitha Saldahna patients with chronic myeloid leukemia: results from a phase 1 study 6.Dr Nikita Mehra 5. Venetoclax in combination with hypomethylating 7.Dr Deepa Philip agents Induces rapid, deep, and durable responses in patients AML ineligible for intensive therapy 6. IL7R expression predicts T-ALL sensitivity to JAK inhibitors regardless of IL7R/JAK/STAT mutational status 7. Enasidenib is highly active in previously untreated IDH2 mutant AML: early results from the BEAT AML master trial 06:10 -06:25 PM Coffee break 06:25 - 07:00 PM **HCC Data Presentation** Dr Deepam Pushpam Dr. Tulika Seth 1. AML 2. ALL Dr Hasmukh Jain Dr. Loknath D Dr Chepsy Phillip Dr Boben Thomas 3. APL Prospective study proposals from the HCC sites – 6 concepts (5+5 minutes) 07:00 -08:00 PM Experts: Dr Hari Menon, Dr.Govind Babu & other international experts 08:00 - 09:00 PM Executive meeting DAY 2 **17TH AUGUST 2019 TOPIC** TIME SPEAKER (S) 07:55-08:00 AM Welcome and Introduction Chairpersons **SESSION 1:** Acute Lymphoblastic Leukemia Dr Tapan Saikia, Dr Subhash Varma 08:00 - 08:30 AM Overview of recent advances in ALL Dr. Charles Mullighan

Biology and its implications  Biology and its implication and ALL (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implications  Biology and its implication and ALL (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its implication and all (Adult ALL Dr. Javachandram  Biology and its impli		Understanding ETP- ALL:				
99:10-10:10 AM Multi-disciplinary team discussion on ALL (Adult ALL logora property of the provided pr	08:30 - 08:50 AM	_	Dr. Manju Sengar			
Description	08:50 - 09:10 AM	Management of AYA - which way to go?	Dr. Prasanth Ganesan			
SESSION 2: Acute Myeloid Leukemia Dr. Harry Erba Dr. Gorind Babu, Dr Velu Nair  10:20 - 10:50 AM Recent advances in biology of AML Dr. Harry Erba Dr. Gorind Babu, Dr Velu Nair  10:50 - 11:30 AM Evolving landscape of de-novo AML therapy Dr. Farhad Ravandi Dr. Harry Erba Dr. Harry Hardy Dr. Harry Harry Dr. Harry Hardy Dr. Harry Harry Dr. Harry	09:10- 10:10 AM	·	Dr. Jayachandran Dr. Anu Korula Dr. Anita Chopra Dr. Kunal Sehgal	Lead discussant - Dr. Manju Sengar		
Dr. Govind Babu, Dr. Velu Nair	10:10-10:20 AM Coffee Break					
13-50 - 11-30 AM	SESSION 2:	Acute Myeloid Leukemia				
11:30 - 12:00 PM Approach to elderly Acute Myeloid Leukemia Dr. Harry Erba  12:00 - 01:00 PM Multi-disciplinary team discussion on AML Dr. Samer Melinkeri Dr. Mayur Parihar Dr. Harry Bland Dr. Lalit Kumar Dr. Neelam Varma Dr. Sundar Jagannath Dr. Neelam Varma Dr. Parihaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Remant Malhotra Dr. Rejiv Kumar Dr. Neelam Varma Dr. Remant Malhotra Dr. Rejiv Kumar Dr. Pankaj Malhotra Dr. Remant Malhotra Dr. Rejiv Kumar Dr. Pankaj Malhotra Dr. Pankaj Malh	10:20 - 10:50 AM	Recent advances in biology of AML	Dr. Harry Erba			
12:00 - 01:00 PM Multi-disciplinary team discussion on AML Dr. Harry Erba Dr. Farhad Ravandi Dr. Sameer Melinkeri Dr. Mayur Parhar Dr. Mayur Mathews Dr. Big Goorge Dr. Atul Sharma Dr. Atul Sharma Dr. Atul Sharma Dr. Atul Sharma Dr. Mayur Parhar Dr. Neelam Varma Dr. Neelam Varma Dr. Neelam Varma Dr. Neelam Varma Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Sharat Damodar Dr. Sharat Damodar Dr. Sharat Damodar Dr. Atul Mayur Dr. Anli Handoo Dr. Arun Kumar A Dr. Arun Kumar A Dr. Arun Kumar A Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Rayir Kumar Dr. Dr. Dinesh Bhurani	10:50 - 11.30 AM	Evolving landscape of de-novo AML therapy	Dr Farhad Ravandi			
12:00 - 01:00 PM Multi-disciplinary team discussion on AML Dr. Farhad Ravandi Dr. Sammer Melliokeri Dr. Mayur Parihar Dr. Vikram Mathews  101:00 - 01:30 PM	11:30 - 12:00 PM	Approach to elderly Acute Myeloid Leukemia	Dr. Harry Erba			
SESSION 3: Acute Promyelocytic Leukemia Current understanding of biology and management Dr. Harry lland  SESSION 4: Multiple Myeloma  O2:15 - O3:00 PM  Recent advances in the of Multiple Myeloma  O3:00 - O3:20 PM  Multi-disciplinary team discussion on Multiple Myeloma  O3:20 - O4:20 PM  Multi-disciplinary team discussion on Multiple Myeloma  O4:20 - O4:30 PM  SESSION 5: Chronic Myeloid Leukemia  O4:30 - O5:00 PM  Chairpersons Dr. Harry lland  Dr. Sundar Jagannath Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Ritu Gupta Dr. Ritu Gupta Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Rajiv Kumar Dr. Hemant Malhotra Dr. Rajiv Kumar  O4:30 - O5:00 PM  Consensus and controversies in front-line therapy of CML Dr. Dinesh Bhurani	12:00 - 01:00 PM	Multi-disciplinary team discussion on AML	Dr Farhad Ravandi Dr Sameer Melinkeri Dr. Mayur Parihar Dr. Smita Kayal			
SESSION 3: Acute Promyelocytic Leukemia Dr. Biju George Dr. Atul Sharma  1:30 - 2:15 PM Acute Promyelocytic Leukemia: Current understanding of biology and management  SESSION 4: Multiple Myeloma Dr. Sundar Jagannath  02:15 - 03:00 PM Recent advances in the of Multiple Myeloma Dr. Sundar Jagannath  03:00 - 03:20 PM How to treat newly diagnosed multiple myeloma Dr. Anup Devasia  03:20 - 04:20 PM Multi-disciplinary team discussion on Multiple Myeloma Dr. Ritu Gupta Dr. Y. Uday Dr. Anil Handoo Dr. Arun Kumar A  SESSION 5: Chronic Myeloid Leukemia Chronic Myeloid Leukemia Dr. Ritu Gupta Dr. Ritu Gupta Dr. Ritu Gupta Dr. Ritu Gupta Dr. Roman Augusta Dr. P. Ritu Gupta Dr. Roman Augusta Dr. P. Roman Augusta Dr. P. Roman Multiple Myeloma Dr. Arun Kumar A  Chairpersons Dr. Hemant Malhotra Dr. Rajiv Kumar  04:30 - 05:00 PM Consensus and controversies in front-line therapy of CML Dr. Timothy Hughes  05:00 - 05:20 PM Toxicities of TKI: Compare and contrast Dr. Dinesh Bhurani	01:00 - 01:30 PM	01:00 - 01:30 PM Lunch				
Acute Promyelocytic Leukemia: Current understanding of biology and management  Dr. Harry Iland  Chairpersons Dr Lalit Kumar Dr. Neelam Varma  Dr. Sundar Jagannath  Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Sharat Damodar Dr. Ritu Gupta Dr. All Handoo Dr. Arun Kumar A  Dr. Pankaj Malhotra  Dr. Pankaj Malhotra  Dr. Pankaj Malhotra  Coffee Break  Chairpersons Dr. Hemant Malhotra Dr. Rajiv Kumar  Dr. Rajiv Kumar  Dr. Rajiv Kumar  Dr. Dinesh Bhurani	SESSION 3:	Acute Promyelocytic Leukemia		Dr Biju George		
SESSION 4: Multiple Myeloma Dr. Lalit Kumar Dr. Neelam Varma  02:15 - 03:00 PM Recent advances in the of Multiple Myeloma Dr. Sundar Jagannath  03:00 - 03:20 PM How to treat newly diagnosed multiple myeloma Dr. Anup Devasia  03:20 - 04:20 PM Multi-disciplinary team discussion on Multiple Myeloma Dr. Sharat Damodar Dr. Ritu Gupta Dr. Anil Handoo Dr. Anun Kumar A  04:20 - 04:30 PM Coffee Break  SESSION 5: Chronic Myeloid Leukemia Chronic Herapy of CML Dr. Timothy Hughes  05:00 - 05:20 PM Toxicities of TKI: Compare and contrast  Dr. Dinesh Bhurani  Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Rajiv Kumar  Clead discussant-Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Hemant Malhotra Dr. Rajiv Kumar	01:30 - 2:15 PM		Dr. Harry Iland			
Dr. Neelam Varma  Dr. Neelam Varma  Dr. Sundar Jagannath  Dr. Anup Devasia  Dr. Sundar Jagannath  Dr. Sarat Damodar  Dr. Ritu Gupta  Dr. Pankaj Malhotra  Dr. Ritu Gupta  Dr. Pankaj Malhotra  Dr. Pankaj Malhotra  Dr. Pankaj Malhotra  Dr. Rijiv Kumar  Dr. Rajiv Kumar  Dr. Rajiv Kumar  Dr. Rajiv Kumar  Dr. Rajiv Kumar  Dr. Dinesh Bhurani				Chairpersons		
03:20 - 04:20 PM How to treat newly diagnosed multiple myeloma  Dr. Anup Devasia  Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Ritu Gupta Dr. Y. Uday Dr. Anil Handoo Dr. Arun Kumar A  Dr. Pankaj Malhotra  Coffee Break  Chronic Myeloid Leukemia  Consensus and controversies in front-line therapy of CML Dr. Timothy Hughes  Dr. Timothy Hughes  Dr. Anup Devasia  Lead discussant- Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Pankaj Malhotra Dr. Rajiv Kumar	SESSION 4:	Multiple Myeloma				
03:20 – 04:20 PM  Multi-disciplinary team discussion on Multiple Myeloma  03:20 – 04:20 PM  Multi-disciplinary team discussion on Multiple Myeloma  Dr. Sundar Jagannath Dr. Sharat Damodar Dr. Ritu Gupta Dr. Anil Handoo Dr. Anil Handoo Dr. Arun Kumar A  Coffee Break  Chronic Myeloid Leukemia  Chairpersons Dr. Hemant Malhotra Dr. Rajiv Kumar  O4:30 - 05:00 PM  Consensus and controversies in front-line therapy of CML Dr. Timothy Hughes  Dr. Dinesh Bhurani	02:15 - 03:00 PM	Recent advances in the of Multiple Myeloma	Dr. Sundar Jagannath			
Multi-disciplinary team discussion on Multiple Myeloma  O3:20 – 04:20 PM  Multi-disciplinary team discussion on Multiple Myeloma  Dr. Sharat Damodar Dr. Ritu Gupta Dr. Anil Handoo Dr. Anil Handoo Dr. Arun Kumar A  Coffee Break  Chronic Myeloid Leukemia  Chairpersons Dr. Hemant Malhotra Dr. Rajiv Kumar  O4:30 - 05:00 PM  Consensus and controversies in front-line therapy of CML Dr. Timothy Hughes  Dr. Dinesh Bhurani	03:00 - 03:20 PM	How to treat newly diagnosed multiple myeloma	Dr. Anup Devasia			
SESSION 5: Chronic Myeloid Leukemia Chairpersons Dr. Hemant Malhotra Dr. Rajiv Kumar  04:30 - 05:00 PM Consensus and controversies in front-line therapy of CML Dr. Timothy Hughes  Dr. Dinesh Bhurani	03:20 - 04:20 PM	Multi-disciplinary team discussion on Multiple Myeloma	Dr. Sharat Damodar Dr. Ritu Gupta Dr. Y. Uday Dr. Anil Handoo			
SESSION 5: Chronic Myeloid Leukemia Dr. Hemant Malhotra Dr. Rajiv Kumar  04:30 - 05:00 PM Consensus and controversies in front-line therapy of CML Dr. Timothy Hughes  05:00 - 05:20 PM Toxicities of TKI: Compare and contrast Dr. Dinesh Bhurani	04:20 - 04:30 PM Coffee Break					
05:00 – 05:20 PM Toxicities of TKI: Compare and contrast Dr. Dinesh Bhurani	SESSION 5:	Chronic Myeloid Leukemia		Dr. Hemant Malhotra		
	04:30 - 05:00 PM	Consensus and controversies in front-line therapy of CML	Dr. Timothy Hughes			
05:20 - 05:50 PM Treatment free remission- is it ready for clinics Dr. Timothy Hughes	05:00 – 05:20 PM	Toxicities of TKI: Compare and contrast	Dr. Dinesh Bhurani			
	05:20 - 05:50 PM	Treatment free remission- is it ready for clinics	Dr. Timothy Hughes			

05:50 – 06:50 PM	Multi-disciplinary team discussion on CML	Dr. Timothy Hughes Dr. Hari Menon Dr. P.G.Subramanian Dr. Kundan Mishra Dr. Aby Abraham Dr. Sanjeevan Sharma Dr Rishi Dhawan	Lead discussant- Dr. Abhay Bhave
07:00 - 08:00 PM		Dinner	
DAY 3	18TH AUGUST 2019		
TIME	TOPIC	SPEAKER (S)	CHAIR (S)
SESSION 6:	Myelodysplastic Syndrome		Chairpersons Dr Karthikeyan Dr Abhay Bhave
08:00 -08:20 AM	MDS: Management of Low risk MDS	Dr Jina Bhattacharya	
08:20 - 08.50 AM	Management of high-risk MDS and secondary AML	Dr. Austin Kulasekaraj	
08:50-09:45 AM	Multi-disciplinary team discussion on MDS	Dr. Austin Kulasekaraj Dr Mayur Parihar Dr Anup Devasia Dr Neeraj Sidharthan Dr Farhad Ravandi Dr Prantar Chakrabarti	Lead discussant- Dr. Biju George
09:45-10:00 AM		Coffee Break	
SESSION 7:	MRD / Recent Advances in Hematology		Chairpersons Dr. Sumeet Gujral Dr K. Pavithran
10:00- 10:30 AM	MRD in ALL: Current status and recent advances	Dr. Charles Mullighan	
10:30 - 10:45 AM	Role of next generation sequencing in myeloid malignancies: <b>Laboratory perspective</b>	Dr. Nikhil Patkar	
10:45 – 11:00 AM	Role of next generation sequencing in myeloid malignancies: <b>Clinicians perspective</b>	Dr. Harry Erba	
11:00 – 11:15 AM	MRD in Myeloma: Laboratory perspective	Dr.Prashant Tembhare	
11:15 – 11:30 AM	MRD in Myeloma: Clinicians perspective	Dr. Sundar Jagannath	
SESSION 8	Breakthrough and recently approved drugs		Chairpersons Dr Manoj Unni Dr Rahul Bhargava
11:30-11:50 AM	Bcl2 inhibitors and hematology	Dr. Atul Sharma	
11:50 - 12:10 PM	Antibody based immunotherapy in hematology	Dr Reetu Jain	
SESSION 9:	Ask the expert session		
12:10 – 01:45 PM	<b>Moderators</b> Dr. Rajan Kapoor Dr. Vikram Mathews		
01:45 – 01:55 PM	Vote of Thanks	Dr. Manju Sengar	

01:55 PM ONWARD	LUNCH					
	II)r Santhoch KI)	Results will be announced before lunch				